Medicine and Dentistry
Malignant Neoplasm
100%
Breast Cancer
80%
Pancreas Cancer
62%
Pancreas Adenocarcinoma
56%
Neoplasm
42%
Symptom
41%
Survivorship in Cancer Care
40%
Overall Survival
37%
Prostate Cancer
36%
Acute Myeloid Leukemia
31%
Patient-Reported Outcome
29%
Health Care Cost
26%
Primary Health Care
25%
Cancer Therapy
22%
Aromatase Inhibitor
22%
Oncology
20%
Disease
19%
Surgery
19%
Positron Emission Tomography-Computed Tomography
17%
Vitamin D
17%
Radiation Therapy
17%
Fluorine-18
17%
Supportive Care
17%
Prostate Specific Membrane Antigen
17%
Clinician
16%
Hazard Ratio
16%
Medicare
16%
Randomized Controlled Trial
15%
Hormone Therapy
15%
Arm
15%
Colorectal Cancer
15%
Surveillance, Epidemiology, and End Results
15%
Clinical Trial
14%
Preventive Medicine
14%
Quality of Life
14%
Prevalence
13%
Intraductal Papillary Mucinous Tumor
13%
Adenocarcinoma
12%
Adjuvant Endocrine Therapy
12%
Cytarabine
12%
Computer Assisted Tomography
12%
Event Free Survival
12%
Nodular Melanoma
12%
Gene Mutation
11%
Odds Ratio
11%
Pancreatic Ductal Adenocarcinoma
11%
Supplementation
11%
Recurrent Disease
11%
Chronic Obstructive Pulmonary Disease
11%
Family History
10%
Keyphrases
Pancreatic Cancer
59%
Pancreatic Ductal Adenocarcinoma
41%
Confidence Interval
29%
Acute Myeloid Leukemia
26%
Survivorship Care Plan
24%
Overall Survival
24%
Breast Cancer
23%
High Risk
20%
Newly Diagnosed
20%
Comorbidity
19%
Risk Factors
16%
Surveillance Epidemiology
16%
Patient-reported Outcomes
15%
Hazard Ratio
14%
Survivors
14%
High-risk Individuals
13%
Patient-Reported Outcomes Measurement Information System (PROMIS)
13%
Chemotherapy
13%
Model Validation
12%
Mitoxantrone
12%
Flavopiridol
12%
Cancer Treatment
12%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Complete Remission
12%
Aromatase Inhibitors
12%
Cancer Survivors
12%
Oncologists
12%
United States
11%
Poor Risk
11%
Early Breast Cancer
10%
Physical Function
10%
Prostate-specific Antigen
10%
Vitamin D Supplementation
10%
Phase II Study
10%
Event-free Survival
10%
QLQ-C30
10%
Randomized Controlled Trial
9%
National Cancer Institute
9%
Graft-versus-host Disease (GvHD)
9%
Elderly Patients
9%
5-year Survival
9%
Cancer Care
9%
Tumor
9%
European Organizations
9%
High-risk Human Papillomavirus (HR-HPV)
9%
Odds Ratio
9%
Vitamin D
9%
Clinical Features
8%
Supportive Care Needs
8%
Cytosine Arabinoside
8%
